PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma

• DOI: 10.1016/j.tranon.2022.101501
• Publication Date: 2022-08-01T18:33:28Z
• Authors: Zhenlin Yang; Yue Peng; Jiachen Xu; Ping Chen; Zhenshan Zhao; Qingyuan Cai; Lin Li; He Tian; Guangyu Bai; Lei Liu; Shugeng Gao; Jie He
• Keywords: TIGIT

PVR/TIGIT and PD-L1/PD-1 axes play essential roles in tumor immune evasion could be potential targets for combined immunotherapy. We aimed to evaluate the expression status of above-mentioned markers lung squamous cell carcinoma (LUSC), investigate their survival impact relevance with microenvironment clinicopathological features. retrospectively collected specimens from 190 LUSC patients, who underwent pulmonary surgeries, we performed immunohistochemistry assays PVR, TIGIT, PD-L1, PD-1 CD8. In our cohort, positive rate PVR was 85.8%, which much higher than PD-L1 at 26.8%. A total 32 (16.8%) patients demonstrated co-expression PVR/PD-L1. High TIGIT density correlated expression, high density, CD8 (PD-L1, P=0.033; PD-1, P<0.001; CD8, P<0.001), (P=0.046). were advanced TNM stage (TIGIT P=0.020; P=0.041). Patients PVR/PD-L1 exhibited a significantly worse prognosis (PVR, P=0.038; P=0.027; PVR/TIGIT, P=0.014; PVR/PD-L1, P=0.018). Multivariate analysis that (Hazard ratio [HR], 1.756, 95% CI, 1.152-2.676, P=0.009) an independent prognostic factor patients. conclusion, LUSC. may serve as predictive biomarker dual-targeting